MedTrace Logo

The Effect of a Weight Management Program During Treatment With Olanzapine

NCT00169702 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2008-01-30

No results posted yet for this study

Summary

The study is a prospective, randomized, open-label study.

Conditions

Interventions

BEHAVIORAL

weight management program

12 sessions, psychoeducation

BEHAVIORAL

weight management program

2 weekly, 12 sessions, psychoeducational weight management

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Else Kröner-Fresenius-Centre for Nutritional Medicine

    collaborator UNKNOWN

  • Technical University of Munich

    collaborator OTHER

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Joachim Cordes, MD · Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University Düsseldorf, Rhineland State Clinics Düsseldorf, Bergische Landstrasse 2, 40629 Düsseldorf, Germany

  • Ansgar Klimke, Prof · Department of Psychiatry, Offenbach

  • Hans Hauner, Prof · Technical University of Munic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2007-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169702 on ClinicalTrials.gov